271 related articles for article (PubMed ID: 24203892)
1. Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target.
Hütt-Cabezas M; Karajannis MA; Zagzag D; Shah S; Horkayne-Szakaly I; Rushing EJ; Cameron JD; Jain D; Eberhart CG; Raabe EH; Rodriguez FJ
Neuro Oncol; 2013 Dec; 15(12):1604-14. PubMed ID: 24203892
[TBL] [Abstract][Full Text] [Related]
2. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Montero JC; Chen X; Ocaña A; Pandiella A
Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
[TBL] [Abstract][Full Text] [Related]
3. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
4. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
[TBL] [Abstract][Full Text] [Related]
5. mTOR pathway as a potential target in a subset of human medulloblastoma.
Pócza T; Sebestyén A; Turányi E; Krenács T; Márk A; Sticz TB; Jakab Z; Hauser P
Pathol Oncol Res; 2014 Oct; 20(4):893-900. PubMed ID: 24737380
[TBL] [Abstract][Full Text] [Related]
6. FilGAP regulates tumor growth in Glioma through the regulation of mTORC1 and mTORC2.
Tsutsumi K; Nohara A; Tanaka T; Murano M; Miyagaki Y; Ohta Y
Sci Rep; 2023 Dec; 13(1):20956. PubMed ID: 38065968
[TBL] [Abstract][Full Text] [Related]
7. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
10. mTOR complex 2 mediates Akt phosphorylation that requires PKCε in adult cardiac muscle cells.
Moschella PC; McKillop J; Pleasant DL; Harston RK; Balasubramanian S; Kuppuswamy D
Cell Signal; 2013 Sep; 25(9):1904-12. PubMed ID: 23673367
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
12. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset.
Jentoft M; Giannini C; Cen L; Scheithauer BW; Hoesley B; Sarkaria JN; Abell-Aleff PC; Rodriguez EF; Li Y; Rodriguez FJ
Int J Clin Exp Pathol; 2010 Dec; 4(1):43-57. PubMed ID: 21228927
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.
Goncharov DA; Kudryashova TV; Ziai H; Ihida-Stansbury K; DeLisser H; Krymskaya VP; Tuder RM; Kawut SM; Goncharova EA
Circulation; 2014 Feb; 129(8):864-74. PubMed ID: 24270265
[TBL] [Abstract][Full Text] [Related]
15. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
[TBL] [Abstract][Full Text] [Related]
16. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.
Poore B; Yuan M; Arnold A; Price A; Alt J; Rubens JA; Slusher BS; Eberhart CG; Raabe EH
Neuro Oncol; 2019 Feb; 21(2):252-263. PubMed ID: 30239952
[TBL] [Abstract][Full Text] [Related]
18. Identification of rictor as a novel substrate of Polo-like kinase 1.
Shao T; Liu X
Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
[TBL] [Abstract][Full Text] [Related]
19. Activation of AMPK/TSC2/PLD by alcohol regulates mTORC1 and mTORC2 assembly in C2C12 myocytes.
Hong-Brown LQ; Brown CR; Navaratnarajah M; Lang CH
Alcohol Clin Exp Res; 2013 Nov; 37(11):1849-61. PubMed ID: 23895284
[TBL] [Abstract][Full Text] [Related]
20. Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells.
Das G; Shiras A; Shanmuganandam K; Shastry P
Mol Carcinog; 2011 Jun; 50(6):412-23. PubMed ID: 21557327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
